Bioxyne subsidiary Breathe Life Sciences (BLS) has imported and irradiated a further 200kg of high-THC cannabis flower across four strains into Australia, with a dispensed patient value of A$3.2 million, as it builds its presence in the local market.
The product will be packed into the company’s Dr Watson brand and sold via special access pathways and supplied in bulk to compounding pharmacies and licensed manufacturers.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and
international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017.
A journalist...
More by Martin Lane